Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
In the Literature
In the Literature
,
Oncology
Pembrolizumab Shows Long-Term Benefits in Metastatic Colorectal Cancer and MSI-H or dMMR
Read More
In the Literature
,
Gastroenterology
,
Oncology
Sitagliptin, DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant
Read More
In the Literature
,
Oncology
Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes
Read More
In the Literature
,
Oncology
Split-Fill Program for Oncology Oral Medications Is Cost-Saving
Read More
In the Literature
,
Oncology
Real-World Evidence Supports Patient Navigation in Cancer
Read More
In the Literature
,
Oncology
Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes
Read More
In the Literature
,
Oncology
Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
Read More
In the Literature
,
Oncology
Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
Read More
In the Literature
,
Oncology
New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
Read More
In the Literature
,
Oncology
Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL
Read More
1
2
Page 1 of 2
Results 1 - 10 of 13